Business
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Cantex forges a licensing deal with vTv Therapeutics and intends to evaluate the vTv drug as a potential treatment for several cancer-related issues.
As part of the announcement, TRexBio indicated that Johnston Erwin had been appointed CEO and Ovid Trifan would be the company’s CMO.
Arrowhead will conduct its activities through preclinical development stages, while Horizon will have sole responsibility for the clinical development and commercialization of the medicine.
Yao has more than 15 years of experience in the cell and gene therapy fields. He also established and directed the Cell Therapy R&D business unit, with a focus on CAR-T development.
GSK CEO Emma Walmsley may face some contentious opposition from key investors interested in forcing a management change following the planned investor update.
Though the world is reopening, this pandemic is not over. Moderna continues expanding production to answer the call globally.
The new U.S. HQ for Neogene has the backing of biotech guru Arie Belldegrun, CEO of Kite Pharma. The company has leased 38,000 sq. ft. in two Santa Monica buildings.
In its announcement, the company did not specify why Kawas’ doctoral research was under investigation, only saying it did not intend to comment on the issue until it had been resolved.
Eisai believes this is a potential-best in class FRα ADC that has shown single agent activity in patients with advanced solid tumors, including endometrial, ovarian, lung and breast cancers.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.